Skip to content
MarketScale
‹ Back to IndustriesHealthcare

COME SEE PRESCO AND PRES-FLEX AND AT MD&M WEST 2019

Presco’s Pres-Flex Booth to be Featured at MD&M West Conference 2019 Presco’s Pres-Flex film division is heading West! This year’s Medical Design & Manufacturing (MD&M) West Conference is scheduled for February 5-7 in Anaheim, California—one of the world’s largest hubs for medical device innovation. Joining thousands of visitors and a wide range of innovative suppliers…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Presco’s Pres-Flex film division is heading West! This year’s Medical Design & Manufacturing (MD&M) West Conference is scheduled for February 5-7 in Anaheim, California—one of the world’s largest hubs for medical device innovation. Joining thousands of visitors and a wide range of innovative suppliers at the Anaheim Convention Center, Pres-Flex is excited to be exhibiting this year in Booth #3097, showcasing what truly sets our medical film and extruded coating processes apart from the rest.

A Reputation for Innovative Insights

The trends driving the global medical manufacturing community change at a rapid pace, making it challenging to keep up. Fortunately, MD&M gathers the top-tier manufacturers, designers and suppliers of medical technology every year for a three-day conference, providing a sneak-peak at the latest innovations and the opportunity to speak directly with the teams who made them possible. Whether it’s developments in 3D printing technology, automation or polymer blends, MD&M puts visitors face-to-face with industry leaders to inspire and propel the community forward. Further, the conference also provides learning opportunities to both visitors and exhibitors alike. With a wide range of sessions, panels and interactive workshops available, MD&M 2019 attendees can rest assured they will leave with priceless insights as to the future direction of medical technology.

Come See Pres-Flex In Person

Please join us at Booth #3097 at MD&M 2019—meet the Pres-Flex team and learn about the superior qualities that our EVA Film and PVC/TPU alloy blends provide for the medical industry. Our alloy blends combine PVC with other polymers to enhance physical attributes, such as abrasion tolerance, tear strength and elongation, while keeping costs low. Pres-Flex also creates custom formulations to meet specific needs, including heavy metal-free, DEHP-free and phthalate-free formulations. When regulations ban PVC content, our EVA film is an excellent alternative, containing no plasticizers while featuring the durability to hold up well in a wide range of environmental conditions. Combining both our custom PVC formulation and EVA film capabilities with our state-of-the-art quality control extrusion system, our USP Class VI certified Medical Film is highly customized, meeting stringent regulatory standards while exceeding medical industry expectations.

Don’t Wait to Check Out Pres-Flex Products

With a history spanning more than 75 years of providing superior solutions for a wide range of industries, Pres-Flex is looking forward to spending time with our friends in the medical community at MD&M 2019. While there, be sure to stop by Booth #3097—our team of professional experts will be on hand discuss how our customization processes can benefit your unique medical film requirements.

To get a leg up on the amazing capabilities of our Pres-Flex products before the show, be sure to visit https://www.pres-flex.com/works/medical/!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512